Journal
VACCINE
Volume 28, Issue 29, Pages 4653-4660Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.04.069
Keywords
Staphylococcus aureus; Vaccine; Economics
Categories
Funding
- Bill and Melinda Gates Foundation
- National Institute of General Medical Sciences Models of Infectious Disease Agent Study (MIDAS) [1U54GM088491-0109]
- Pennsylvania Department of Health
- Vaccine Modeling Initiative (VMI)
Ask authors/readers for more resources
The continuing morbidity and mortality associated with Staphylococcus aureus (S. aureus) infections, especially methicillin-resistant S. aureus (MRSA) infections, have motivated calls to make S. aureus vaccine development a research priority. We developed a decision analytic computer simulation model to determine the potential economic impact of a S. aureus vaccine for neonates. Our results suggest that a S. aureus vaccine for the neonatal population would be strongly cost-effective (and in many situations dominant) over a wide range of vaccine efficacies (down to 10%) for vaccine costs (<=$500), and S. aureus attack rates (>= 1%). (C) 2010 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available